Sarepta Therapeutics Inc. may find itself on the forefront of endpoint development in Duchenne muscular dystrophy after FDA's accelerated approval of Exondys 51.
Duchenne Development: Six-Minute Walk Losing Favor?
Sarepta relied on the endpoint to get accelerated approval for eteplirsen, but the interim CEO says trials for follow-on products could use walk-run tests or other measures instead.